NOTE: If a DLT occurs in Group 1 or Group 2 which requires expansion of the group (n=6), then a 14-day stagger would be implemented in Group 2 or 3, respectively. The study will enroll 12-24 subjects to evaluate DLTs and determine target dose. The sample size of the target cell dose may be expanded up to 10 subjects to characterize safety and any preliminary evidence of antitumor activity. The Safety Review Committee (SRC) may recommend adding additional patients to a given group (not to exceed 9 subjects in total in any group apart from target dose expansion group) resulting in a potential maximum number of 37 subjects treated.